Trial · NCT02690714
Adverse events171
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 171
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Lymph node pain | Blood and lymphatic system disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 2 | 15 | |
| other | Cardiac flutter | Cardiac disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Ehlers-Danlos syndrome | Congenital, familial and genetic disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Deafness unilateral | Ear and labyrinth disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Ear pain | Ear and labyrinth disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 2 | 15 | |
| other | Excessive cerumen production | Ear and labyrinth disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Hypoacusis | Ear and labyrinth disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Motion sickness | Ear and labyrinth disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Tinnitus | Ear and labyrinth disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Tympanic membrane perforation | Ear and labyrinth disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Conjunctival deposit | Eye disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Eye discharge | Eye disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 2 | 15 | |
| other | Eye inflammation | Eye disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Eye irritation | Eye disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Eye pain | Eye disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Eye swelling | Eye disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Ocular hyperaemia | Eye disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 | |
| other | Abdominal discomfort | Gastrointestinal disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 2 | 15 | |
| other | Abdominal distension | Gastrointestinal disorders | 6.6 mg/kg Plasminogen (Human) Intravenous | 1 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02690714/events